Login
$NXTC
$6.68 +$0.28 (4.37%) Live

$NXTC 8-K SEC Filings

Filed On Filing
10 Nov 2026 8-K: Results of Operations and Financial Condition

Advancing Toward Stockholder Approval of Proposed Merger with Avere Therapeutics Supported by Approximately $820 Million of Committed Financing

30 Oct 2026 8-K: Departure/Election of Directors or Officers; Compensation

On October 26, 2026 NextCure, Inc. (the “Company”) determined that the employment of Dr. Udayan Guha, M.D., Ph.D., Chief Medical Officer and a named executive officer of the Company, will be terminated effective October 31, 2026, in cont...

25 Sep 2026 8-K: Other Events

Petitioner NextCure, Inc. (“NextCure” or the “Company”), by and through its undersigned counsel, brings this petition pursuant to 8 Del. C. § 205, seeking to have this Court validate a potentially defective corporate act as follows:

03 Sep 2026 8-K: Entry into a Material Definitive Agreement

This NINTH AMENDMENT TO LEASE AGREEMENT (“this Ninth Amendment”) is dated as of August 28, 2026 (“Effective Date”), by and between ARE-8000/9000/10000 VIRGINIA MANOR, LLC, a Delaware limited liability company, having an address at 26 Nor...

06 Aug 2026 8-K: Results of Operations and Financial Condition

Preserving Capital in Support of Merger Closing; Continuing Clinical Transition and Legacy Asset Activities

14 Jul 2026 8-K: Entry into a Material Definitive Agreement; Costs Associated with Exit or Disposal Activities +4 more

First Certificate of Merger, including certificate of incorporation of the First Step Surviving Corporation attached as Exhibit A thereto, incorporated by reference into this Agreement

25 Jun 2026 8-K: Departure/Election of Directors or Officers; Compensation; Submission of Matters to a Vote of Security Holders

10.TERMS AND CONDITIONS OF RESTRICTED STOCK, RESTRICTED STOCK UNITS, AND DEFERRED STOCK UNITS‌20

01 Jun 2026 8-K: Regulation FD Disclosure; Other Events

55% ORR in gynecologic cancers with 52.9% in ovarian and 66.7% in USC at 12 weeks by best response per RECIST 1.1 within the therapeutic dose range (4.8 – 8.0 mg/kg)

07 May 2026 8-K: Results of Operations and Financial Condition

SIM0505/CDH6 ADC dose optimization initiated in gynecologic cancers

05 Mar 2026 8-K: Results of Operations and Financial Condition

Data readout for SIM0505/CDH6 ADC Phase 1 dose escalation study and initiation of dose optimization in ovarian cancer are both anticipated in Q2 2026

23 Jan 2026 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure +1 more

NASDAQ: NXTC SIM0505 LNCB74 J A N U A R Y 2 0 2 6 Corporate Presentation

19 Dec 2025 8-K: Other Events

NextCure, Inc., a corporation organized under the laws of Delaware (the “Company”), confirms its agreement (this “Agreement”) with H.C. Wainwright & Co., LLC (the “Manager”) as follows:

17 Nov 2025 8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities +2 more

[***] CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN EXCLUDED PURSUANT TO REGULATION S-K, ITEM 601(B)(10). SUCH EXCLUDED INFORMATION IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.

05 Nov 2025 8-K: Results of Operations and Financial Condition

BELTSVILLE, Md. – November 5, 2025 – NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class, and best-in-class therapies to treat cancer, today provided a b...

25 Aug 2025 8-K: Departure/Election of Directors or Officers; Compensation

On August 21, 2025, Solomon Langermann, Ph.D., resigned from his position as Chief Scientific Officer of NextCure, Inc. (the “Company”), effective September 1, 2025. Dr. Langermann’s decision to resign was not the result of any disagreem...

07 Aug 2025 8-K: Results of Operations and Financial Condition

Announced strategic partnership with Simcere Zaiming for Phase 1 program SIM0505 (CDH6 ADC) with plans to dose the first SIM0505 patient in the United States this quarter

14 Jul 2025 8-K: Material Modification to Rights of Security Holders; Amendments to Articles/Bylaws; Change in Fiscal Year

NextCure, Inc. (the “Corporation”), a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware, hereby certifies as follows:

10 Jul 2025 8-K: Other Events

On July 10, 2025, NextCure, Inc., a Delaware corporation (the “Company”), announced that its board of directors approved a one-for-twelve (1:12) reverse stock split of its common stock (the “Reverse Stock Split”).

23 Jun 2025 8-K: Submission of Matters to a Vote of Security Holders

On June 20, 2025, the Company held its 2025 Annual Meeting of Stockholders (the “Annual Meeting”). At the Annual Meeting, the Company’s stockholders: (i) elected the three Class III members of the Board of Directors (the “Board”), each t...

16 Jun 2025 8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities +2 more

This Registration Rights Agreement (this “Agreement”) is made and entered into as of June 13, 2025, by and among NextCure, Inc., a Delaware corporation (the “Company”), and Simcere Zaiming, Inc., a Delaware corporation (the “Investor”).

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support